ATE437963T1 - In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase - Google Patents
In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blaseInfo
- Publication number
- ATE437963T1 ATE437963T1 AT04723215T AT04723215T ATE437963T1 AT E437963 T1 ATE437963 T1 AT E437963T1 AT 04723215 T AT04723215 T AT 04723215T AT 04723215 T AT04723215 T AT 04723215T AT E437963 T1 ATE437963 T1 AT E437963T1
- Authority
- AT
- Austria
- Prior art keywords
- cell carcinoma
- vitro method
- transitional cell
- bladder
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200300708 | 2003-03-26 | ||
PCT/EP2004/003219 WO2004085676A1 (en) | 2003-03-26 | 2004-03-25 | In vitro method to detect bladder transitional cell carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE437963T1 true ATE437963T1 (de) | 2009-08-15 |
Family
ID=33041266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04723215T ATE437963T1 (de) | 2003-03-26 | 2004-03-25 | In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase |
Country Status (7)
Country | Link |
---|---|
US (1) | US8124331B2 (de) |
EP (1) | EP1611252B1 (de) |
AT (1) | ATE437963T1 (de) |
DE (1) | DE602004022266D1 (de) |
DK (1) | DK1611252T3 (de) |
ES (1) | ES2330634T3 (de) |
WO (1) | WO2004085676A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
US9089601B2 (en) | 2006-07-10 | 2015-07-28 | University Of Rochester | Pre- and intra-operative imaging of bladder cancer |
ES2323927B1 (es) * | 2007-03-30 | 2010-05-14 | Laboratorios Salvat, S.A. | Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga. |
WO2010002862A2 (en) * | 2008-07-01 | 2010-01-07 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (fgfr3) binding proteins |
CA2754163C (en) | 2009-03-25 | 2019-04-09 | Genentech, Inc. | Anti-fgfr3 antibodies and methods using same |
US20140030259A1 (en) * | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
EP2902489B9 (de) * | 2012-09-27 | 2018-02-07 | Chugai Seiyaku Kabushiki Kaisha | Fgfr3-fusionsgen und darauf gerichteter pharmazeutischer wirkstoff |
JP6766037B2 (ja) * | 2014-09-26 | 2020-10-07 | ヤンセン ファーマシューティカ エヌ.ベー. | Fgfr阻害剤による治療に応答性であるがん患者を同定する際の、fgfr変異遺伝子パネルの使用 |
US11360092B2 (en) | 2016-08-05 | 2022-06-14 | The Research Foundation For The State University Of New York | Keratin 17 as a biomarker for bladder cancer |
BR112023002455A2 (pt) | 2020-08-21 | 2023-03-28 | Genzyme Corp | Anticorpos fgfr3 e métodos de uso |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030087854A1 (en) * | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
DE60032910T3 (de) * | 1999-05-05 | 2010-07-29 | Institut Curie | Mittel zum nachweis und zur behandlung von krankheiten die in verbindung stehen mit fgfr3 |
ATE440869T1 (de) * | 2001-06-20 | 2009-09-15 | Fibron Ltd | Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon |
-
2004
- 2004-03-25 AT AT04723215T patent/ATE437963T1/de not_active IP Right Cessation
- 2004-03-25 EP EP04723215A patent/EP1611252B1/de not_active Expired - Lifetime
- 2004-03-25 ES ES04723215T patent/ES2330634T3/es not_active Expired - Lifetime
- 2004-03-25 WO PCT/EP2004/003219 patent/WO2004085676A1/en active Application Filing
- 2004-03-25 DE DE602004022266T patent/DE602004022266D1/de not_active Expired - Lifetime
- 2004-03-25 US US10/550,608 patent/US8124331B2/en active Active
- 2004-03-25 DK DK04723215T patent/DK1611252T3/da active
Also Published As
Publication number | Publication date |
---|---|
DK1611252T3 (da) | 2009-11-23 |
DE602004022266D1 (de) | 2009-09-10 |
EP1611252B1 (de) | 2009-07-29 |
US20070092878A1 (en) | 2007-04-26 |
EP1611252A1 (de) | 2006-01-04 |
US8124331B2 (en) | 2012-02-28 |
ES2330634T3 (es) | 2009-12-14 |
WO2004085676A1 (en) | 2004-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bellamri et al. | Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib | |
Emslie et al. | Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial | |
Kottmann et al. | Pharmacologic inhibition of lactate production prevents myofibroblast differentiation | |
Gould et al. | Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice | |
CY1118566T1 (el) | Διαγνωση με χρηση ιντερφερονης τυπου 1 | |
BR0308290A (pt) | Tratamento e prevenção de distúrbios inflamatórios | |
NO20044462L (no) | Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer | |
EP3112476A3 (de) | Verfahren, zusammensetzungen, verwendungen und kits für vitamin-d-mangel und verwandten erkrankungen | |
Liu et al. | Ursodeoxycholic acid attenuates acute aortic dissection formation in angiotensin II-infused apolipoprotein E-deficient mice associated with reduced ROS and increased Nrf2 levels | |
BRPI0810336A2 (pt) | "método para tratar e/ou prevenir úlceras de pele em um indivíduo" | |
AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
DE69920940D1 (de) | Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte | |
SG146653A1 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
ATE263371T1 (de) | Therapeutisches agenz mit quantitativem verbrauchsmarker und methode zum nachweis des agenzverbrauchs | |
ATE437963T1 (de) | In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase | |
PL1889920T3 (pl) | Sposób identyfikacji związków do terapii antynowotworowej in vitro | |
Padilla et al. | Blood pressure regulation VIII: resistance vessel tone and implications for a pro-atherogenic conduit artery endothelial cell phenotype | |
Zhao et al. | Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells | |
Margue et al. | Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells | |
BRPI0507958A (pt) | biomarcadores | |
Podkowa et al. | A novel mGlu4 selective agonist LSP4-2022 increases behavioral despair in mouse models of antidepressant action | |
WO2006047475A3 (en) | Detection and analysis of ophthalmically-relevant fluorescent molecules | |
ATE348630T1 (de) | Verminderung der nebenwirkungen der chemotherapie in krebspatienten | |
MX2009001070A (es) | Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma. | |
WO2020176654A8 (en) | Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |